Metals and oxidative homeostasis in Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 293, doi. 10.1002/ddr.10099
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2002 AND VI 56 AND IP 3
Results: 26
1
2
Selective estrogen receptor modulators (SERM) for the brain: Recent advances and remaining challenges for developing a NeuroSERM™.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 380, doi. 10.1002/ddr.10090
- By:
- Publication type:
- Article
3
Hippocampal structure and the action of cholinomimetic drugs.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 531, doi. 10.1002/ddr.10106
- By:
- Publication type:
- Article
4
Metal ion chelation in neurodegenerative disorders.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 300, doi. 10.1002/ddr.10083
- By:
- Publication type:
- Article
5
Development of antiinflammatory therapy for Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 421, doi. 10.1002/ddr.10094
- By:
- Publication type:
- Article
6
Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 347, doi. 10.1002/ddr.10087
- By:
- Publication type:
- Article
7
Transglutaminase-mediated crosslinking of neural proteins in Alzheimer's disease and other primary dementias.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 458, doi. 10.1002/ddr.10098
- By:
- Publication type:
- Article
8
Role of insulin in Alzheimer's disease:approaches emerging from basic animal research and neurocognitive studies in humans.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 511, doi. 10.1002/ddr.10101
- By:
- Publication type:
- Article
9
The case for iron chelation and/or antioxidant therapy in Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 526, doi. 10.1002/ddr.10105
- By:
- Publication type:
- Article
10
Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 282, doi. 10.1002/ddr.10082
- By:
- Publication type:
- Article
11
Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 415, doi. 10.1002/ddr.10093
- By:
- Publication type:
- Article
12
Preclinical experiments on cognition enhancement in Alzheimer's disease: Drugs affecting nicotinic acetylcholine receptors.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 335, doi. 10.1002/ddr.10086
- By:
- Publication type:
- Article
13
Oxidative imbalance and lipid peroxidation in Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 446, doi. 10.1002/ddr.10097
- By:
- Publication type:
- Article
14
Role of GSK-3β in Alzheimer's disease pathology.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 491, doi. 10.1002/ddr.10100
- By:
- Publication type:
- Article
15
Melatonin in aging and neurodegeneration.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 482, doi. 10.1002/ddr.10104
- By:
- Publication type:
- Article
16
Current drug targets for Alzheimer's disease treatment.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 267, doi. 10.1002/ddr.10081
- By:
- Publication type:
- Article
17
Role of meta-analysis of clinical trials for Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 401, doi. 10.1002/ddr.10092
- By:
- Publication type:
- Article
18
Talsaclidine (WAL 2014 FU), a muscarinic M<sub>1</sub> receptor agonist for the treatment of Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 321, doi. 10.1002/ddr.10085
- By:
- Publication type:
- Article
19
From cyclooxygenase activities to Alzheimer's disease neuropathology:experimental approaches and therapeutic interventions.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 438, doi. 10.1002/ddr.10096
- By:
- Publication type:
- Article
20
Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 369, doi. 10.1002/ddr.10089
- By:
- Publication type:
- Article
21
Peptides as drug candidates against Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 475, doi. 10.1002/ddr.10103
- By:
- Publication type:
- Article
22
Neuroprotective properties of topiramate in organotypic hippocampal cultures: implications for treatment of vascular and other dementias.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 393, doi. 10.1002/ddr.10091
- By:
- Publication type:
- Article
23
Use of vitamin C and E in the treatment of Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 452, doi. 10.1002/ddr.10107
- By:
- Publication type:
- Article
24
Orally active and selective benzylidene ketal M<sub>2</sub> muscarinic receptor antagonists for the treatment of Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 310, doi. 10.1002/ddr.10084
- By:
- Publication type:
- Article
25
Elevated glutathione as a therapeutic strategy in Alzheimer's disease.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 428, doi. 10.1002/ddr.10095
- By:
- Publication type:
- Article
26
Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor.
- Published in:
- Drug Development Research, 2002, v. 56, n. 3, p. 354, doi. 10.1002/ddr.10088
- By:
- Publication type:
- Article